Literature DB >> 6184998

The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy for diabetic retinopathy.

T A Rice, R G Michels, M G Maguire, E F Rice.   

Abstract

We analyzed a consecutive series of 596 eyes that underwent vitrectomy for complications of diabetic retinopathy to determine the postoperative incidence of iris neovascularization and neovascular glaucoma. Survival curves for various factors were plotted, showing the cumulative incidence of these complications at various postoperative times up to one year. Eyes in which the lens was removed during vitrectomy had a statistically significant (P less than .001 by log-rank test) increase in the postoperative incidence of both iris neovascularization and neovascular glaucoma compared to eyes in which the lens was not removed. Lens removal at vitrectomy increased the risk of postoperative iris neovascularization by a factor of more than three and the risk of neovascular glaucoma by a factor of more than four. Other factors associated with a significantly increased incidence of postoperative iris neovascularization were severe preoperative retinal neovascularization and the absence of preoperative scatter retinal photocoagulation. Neither of these two factors nor postoperative retinal detachment invalidated or reduced the effect of lensectomy on increased postoperative iris neovascularization when all factors were considered simultaneously. This study showed a statistically significant increase in the postoperative incidence of neovascular glaucoma in eyes undergoing combined lensectomy and vitrectomy compared to eyes in which the lens was not removed.

Entities:  

Mesh:

Year:  1983        PMID: 6184998     DOI: 10.1016/0002-9394(83)90328-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  21 in total

1.  Effect of oxygen tension on the quantities of procollagenase-activating angiogenic factor present in the developing kitten retina.

Authors:  C M Taylor; J B Weiss; R D Kissun; A Garner
Journal:  Br J Ophthalmol       Date:  1986-03       Impact factor: 4.638

2.  Primate model of neovascular glaucoma.

Authors:  A J Packer; X Q Gu; E G Servais; S S Hayreh
Journal:  Int Ophthalmol       Date:  1986-05       Impact factor: 2.031

3.  Factors influencing the results of vitreous surgery in diabetic retinopathy. I. Iris rubeosis and/or active neovascularization at the fundus.

Authors:  J Oldendoerp; M Spitznas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

Review 4.  Current management of vitreous hemorrhage due to proliferative diabetic retinopathy.

Authors:  Jaafar El Annan; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

5.  Extracapsular cataract extraction in diabetic eyes. The role of YAG laser capsulotomy.

Authors:  N Tsopelas; N Kokolakis; D Droutsas; G Theodossiadis
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

6.  Cystoid macular oedema after extracapsular cataract extraction and intraocular lens implantation in diabetic patients without retinopathy.

Authors:  U Menchini; F Bandello; R Brancato; F I Camesasca; M Galdini
Journal:  Br J Ophthalmol       Date:  1993-04       Impact factor: 4.638

7.  Biomicroscopy versus fluorescein angiography of the iris in the detection of diabetic iridopathy.

Authors:  F Bandello; R Brancato; R Lattanzio; B Falcomatà; A Malegori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-08       Impact factor: 3.117

Review 8.  Surgery for Diabetic Eye Complications.

Authors:  María H Berrocal; Luis A Acaba; Alexandra Acaba
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 9.  Physiology of vitreous surgery.

Authors:  Einar Stefánsson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-26       Impact factor: 3.117

10.  Significance of various systemic and ocular parameters in the long-term prognosis after diabetic vitrectomy.

Authors:  P Summanen
Journal:  Int Ophthalmol       Date:  1989-09       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.